Novartis reports late-stage trial failure for neuromuscular drug candidate del-desiran
Novartis announced that its experimental drug del-desiran failed to meet its primary endpoint in a late-stage trial for myotonic dystrophy, a muscle-wasting disorder. The setback marks the second major trial failure for Novartis within days. The company's shares fell approximately 9 percent following the announcement.
11
Divergence score
3 outlets covered it, splitting into 3 framing camps across 3 bias groups.
3 camps
3 bias groups
Market signalBETA
The spectrum · how 3 outlets placed this story
LeftCenterRight
Wall Street Journal
Globe and Mail
Reuters
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
Furthest apart on this story
Wall Street Journal
Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial
clinical trial outcome · neutral
Globe and Mail
Novartis shares fall after second major trial setback in days
repeated pipeline failures · negative
First to report
- Reutersfirst
- Wall Street Journal+5.2 h
- Globe and Mail+11.3 h
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
The split, in one line
All outlets report the same trial failure, but the Globe and Mail emphasizes second major trial setback in days while Reuters frames it as a fresh pipeline blow and WSJ keeps it clinical.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 3 outlets
“Novartis shares fall after second major trial setback in days”
“Novartis sinks as muscle wasting drug setback delivers fresh pipeline blow”
“Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial”
3 tracked claims across 3 outlets
Fact ledger
All3Corroborated3
3/3
Corroborated
Novartis's drug del-desiran failed to meet its primary endpoint in a late-stage trial for myotonic dystrophy
Corroborated
Disputed
2 more tracked claimsSign up free to see the full ledger